The candidates merge two existing vaccines that have demonstrated favourable tolerability through randomised controlled ...
US FDA grants fast track designation to two Sanofi’s combination vaccine candidates to prevent influenza & Covid-19 infections: Paris Thursday, December 12, 2024, 10:00 Hrs [IST ...
The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates ...
A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental ...
The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and ...
Paris: The US Food and Drug Administration (USFDA) has granted Fast Track designation to two Sanofi combination vaccine ...
Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and ...
The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback